type in your search and press enter
Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate
You May Also Like
NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology’s Annual Meeting
NANOBIOTIX: PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 ...
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
- Company expediting planned dose escalation activities - - Low levels of SGT-001 microdystrophin ...
SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
Study initiation marks important milestone following promising clinical results in previous Phase 2 study ...